Literature DB >> 33489447

Cancer immunotherapy: a promising dawn in cancer research.

Banashree Bondhopadhyay1, Sandeep Sisodiya1, Atul Chikara1, Asiya Khan2, Pranay Tanwar2, Dil Afroze3, Neha Singh4, Usha Agrawal5, Ravi Mehrotra1, Showket Hussain1.   

Abstract

Cancer is a highly proliferative disease, which is caused due to the loss of regulation of cell cycle and apoptosis, DNA damage, faulty repair system etc. The cancer microenvironment plays a pivotal role in disease progression as they contain different types of innate and adaptive immune cells. The most important molecules that establish a correlation between inflammation, innate immunity, adaptive immunity, and cancer are the molecules released by inflammatory cells in cancer microenvironment. These molecules secreted by the immune cells, which might activate a pro-tumorigenic and anti-tumorigenic response in cancer. In inflammatory microenvironment, the equilibrium state of immunosuppressive and immunostimulatory signals are important in tumor suppression. The immunotherapeutic approaches could be more effective in cancer treatment. However, advancement in immunobiology and cancer are improving the prospects of immunotherapy alone and/or in combination with the conventional therapies. Thus, the review attempts to highlight a promising and futuristic immunotherapeutic approach in combination with conventional treatment modalities. AJBR
Copyright © 2020.

Entities:  

Keywords:  Cancer; adaptive immunity; immunotherapies; innate immunity; oncolytic viruses and bacteria; tumor-immuno printing strategy

Year:  2020        PMID: 33489447      PMCID: PMC7811907     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  58 in total

Review 1.  Immune responses in cancer.

Authors:  Jamila K Adam; Bharti Odhav; Kanti D Bhoola
Journal:  Pharmacol Ther       Date:  2003-07       Impact factor: 12.310

2.  Therapeutic antibodies, vaccines and antibodyomes.

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-14       Impact factor: 5.857

Review 3.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

Review 4.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.

Authors:  Mark J Smyth; Gavin P Dunn; Robert D Schreiber
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

5.  Imiquimod, a topical immune response modifier, induces migration of Langerhans cells.

Authors:  H Suzuki; B Wang; G M Shivji; P Toto; P Amerio; M A Tomai; R L Miller; D N Sauder
Journal:  J Invest Dermatol       Date:  2000-01       Impact factor: 8.551

6.  Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.

Authors:  Yunfei Zhang; Baoan Ma; Yong Zhou; Minghua Zhang; Xiuchun Qiu; Yanfang Sui; Xiumin Zhang; Bin Ma; Qingyu Fan
Journal:  Breast Cancer Res Treat       Date:  2006-12-23       Impact factor: 4.872

7.  Spectrum of breast cancer in Asian women.

Authors:  Gaurav Agarwal; P V Pradeep; Vivek Aggarwal; Cheng-Har Yip; Polly S Y Cheung
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

8.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 9.  Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now.

Authors:  Mausumi Bharadwaj; Gaurav Roy; Koushik Dutta; Mohammad Misbah; Mohammad Husain; Showket Hussain
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

Review 10.  Immunotherapy of cancer: reprogramming tumor-immune crosstalk.

Authors:  Kyle K Payne; Amir A Toor; Xiang-Yang Wang; Masoud H Manjili
Journal:  Clin Dev Immunol       Date:  2012-10-11
View more
  6 in total

Review 1.  Cancer Immunotherapies: What the Perioperative Physician Needs to Know.

Authors:  Robert S Ackerman; Aaron R Muncey; Nasrin N Aldawoodi; Rohini Kotha; Rosemarie E Garcia Getting
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.945

2.  Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.

Authors:  Holly Butler; Omar Saulat; Barbara-Ann Guinn
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

Review 3.  Checkpoint Inhibitors and the Gut.

Authors:  Tuan Tran; Nguyen Giang Tien Tran; Vincent Ho
Journal:  J Clin Med       Date:  2022-02-04       Impact factor: 4.241

4.  The nomogram based on the 6-lncRNA model can promote the prognosis prediction of patients with breast invasive carcinoma.

Authors:  Dankun Luo; Wenchao Yao; Qiang Wang; Qiu Yang; Xuxu Liu; Yang Yang; Weihui Zhang; Dongbo Xue; Biao Ma
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.379

Review 5.  Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment.

Authors:  Jeong-Yeon Mun; Sun-Hee Leem; Jun Ho Lee; Hyuk Soon Kim
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

Review 6.  Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

Authors:  Nirmala Tilija Pun; Chul-Ho Jeong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.